Comprehensive Biocompatibility Compliance Services for Medical Devices
Accelerate global market access while ensuring the highest standards of patient safety with Masuu Global Solution’s Biocompatibility Compliance Services for Medical Devices. From ISO 10993 risk assessments to complete biological evaluations, we provide end‑to‑end support that helps manufacturers meet worldwide regulatory requirements with precision and confidence.
Our experts combine scientific rigor, regulatory insight, and efficient methodologies to help you demonstrate biological safety, reduce unnecessary testing, and achieve faster regulatory approvals.
Overview
At Masuu Global Solutions, we recognize that patient safety is the foundation of every medical device. Biocompatibility evaluation is a critical component of global regulatory submissions—ensuring that device materials interact safely with the human body under intended use conditions.
With increasingly stringent standards across ISO 10993, EU MDR, and other international frameworks, manufacturers need a trusted partner who can navigate biological evaluation requirements with accuracy, clarity, and efficiency.
- Reduce the need for animal testing through risk‑based approaches
- Optimize biological evaluations with the latest scientific methodologies
- Support quicker and smoother approvals across global markets
- Strengthen patient safety and long‑term device performance
Partnering with Masuu gives you access to scientific toxicologists, risk assessors, and regulatory experts dedicated to guiding your device from concept to commercialization.
Our Comprehensive Biocompatibility Services
Masuu Global Solutions offers a full suite of services to help manufacturers meet biological safety requirements across different device categories and market regions.
✔ Biological Evaluation (ISO 10993 & EU MDR)
Complete biological evaluations that incorporate device materials, design, intended patient exposure, and real‑world use. We ensure all evaluations align with:- ISO 10993‑1: Biological Evaluation Framework
- EU MDR Annex I (GSPRs)
- FDA and international biological safety expectations
✔ Gap Analysis & Regulatory Roadmap
We identify missing, outdated, or non‑compliant elements in your biological evaluation package, followed by a prioritized action plan that:- Addresses testing gaps
- Minimizes redundant studies
- Ensures full alignment with ISO 10993 & MDR requirements
- Reduces delays during Notified Body or FDA review
✔ Toxicological Risk Assessments (TRA) for Extractables & Leachables (E&L)
A thorough toxicological evaluation of chemical compounds that may migrate from your device during use. This includes:- Identification of extractable/leachable chemicals
- Quantification of substance concentrations
- Toxicological hazard characterization
- Exposure and margin of safety calculations
- ISO 10993‑17‑aligned safety justifications
Our risk‑based approach ensures your device meets all chemical safety requirements while avoiding unnecessary testing.
✔ Predicate Device Strategy
We leverage data from legally marketed predicate devices to:- Reduce testing burden
- Decrease time‑to‑market
- Support comparative safety justification
- Strengthen regulatory submissions
This strategy is especially useful under EU MDR, FDA pathways, and markets with accelerated review mechanisms.
✔ Risk Mitigation & Safety Strategy
We evaluate biological hazards based on:- Severity
- Probability
- Extent of patient exposure
- Material‑related hazards
- Chemical exposures
- Use‑related biological risks
- Long‑term safety concerns
✔ Biocompatibility Study Design & Monitoring
Every device has unique biological evaluation needs. Masuu ensures customized study design aligned with:- Device materials
- Physical and chemical characterization
- Intended use & duration of contact
- ISO 10993 test selection
We oversee the entire study lifecycle—from protocol development to test monitoring and final reporting—to ensure regulatory‑ready output.
✔ Safety Justifications & Analysis
We prepare scientific justifications that:- Explain testing decisions
- Support alternative methods in place of animal tests
- Provide transparent, data‑driven conclusions
- Strengthen your submission’s biological safety narrative
These justifications are essential for EU MDR assessments, FDA submissions, and Notified Body reviews.
Biological Evaluation as per EU MDR & ISO 10993 Biological Evaluation Plan (BEP) A BEP outlines the strategy for determining biological safety. Masuu prepares risk‑based, scientifically supported BEPs that include:- Biological endpoints applicable to your device
- Material characterization strategy
- Rationale for test selection and exclusions
- All regulatory, scientific, and toxicological inputs
- Comprehensive review of all test results
- Toxicological assessment of extractables & leachables
- Integration of chemical, biological, and clinical evidence
- Final conclusions supporting biological safety and compliance
